Brief update on the LEADER cardiovascular outcomes trial
Video navigation menu
- Aim and design of the LEADER trial 00:34
- Primary and key secondary cardiovascular outcomes 02:15
- What about patients with versus those without prior ischemic event? 04:01
- Occurrence of severe hypoglycaemia over time 05:19
- Summary of results 06:48
Persons with type 2 diabetes are at an elevated risk for cardiovascular disease. Results of several recent cardiovascular outcomes trials indicate that selected GLP-1 agonists have significant cardiovascular benefits. This recording aims to highlight the practical implications of the LEADER study data with the GLP-1 agonist liraglutide.
Prof. Neil Poulter, FMedSci, cardiologist, Faculty of Medicine, National Heart & Lung Institute; Professor of Preventive Cardiovascular Medicine, Imperial College London, United Kingdom
Member of the Executive Board and President Elect of the International Society of Hypertension
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.